WO2010005012A1 - アポラクトフェリン含有組成物 - Google Patents
アポラクトフェリン含有組成物 Download PDFInfo
- Publication number
- WO2010005012A1 WO2010005012A1 PCT/JP2009/062411 JP2009062411W WO2010005012A1 WO 2010005012 A1 WO2010005012 A1 WO 2010005012A1 JP 2009062411 W JP2009062411 W JP 2009062411W WO 2010005012 A1 WO2010005012 A1 WO 2010005012A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- apolactoferrin
- solution
- derived
- age
- glyceraldehyde
- Prior art date
Links
- 108010038047 apolactoferrin Proteins 0.000 title claims abstract description 90
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 34
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 30
- 239000005862 Whey Substances 0.000 claims abstract description 24
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 24
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 24
- 239000011230 binding agent Substances 0.000 claims abstract description 24
- 235000013336 milk Nutrition 0.000 claims abstract description 24
- 239000008267 milk Substances 0.000 claims abstract description 24
- 210000004080 milk Anatomy 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 23
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 22
- 102000005593 Endopeptidases Human genes 0.000 claims abstract description 8
- 108010059378 Endopeptidases Proteins 0.000 claims abstract description 8
- 102000018389 Exopeptidases Human genes 0.000 claims abstract description 8
- 108010091443 Exopeptidases Proteins 0.000 claims abstract description 8
- 101710118538 Protease Proteins 0.000 claims abstract description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 3
- 230000036252 glycation Effects 0.000 claims description 27
- 239000007795 chemical reaction product Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 abstract description 42
- 238000002360 preparation method Methods 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 11
- 239000000654 additive Substances 0.000 abstract description 5
- 239000002537 cosmetic Substances 0.000 abstract description 5
- -1 deodorizers Substances 0.000 abstract description 5
- 239000003599 detergent Substances 0.000 abstract description 5
- 108010005094 Advanced Glycation End Products Proteins 0.000 abstract description 4
- 239000011248 coating agent Substances 0.000 abstract description 3
- 239000002304 perfume Substances 0.000 abstract description 3
- 229920000642 polymer Polymers 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 50
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 32
- 108010063045 Lactoferrin Proteins 0.000 description 31
- 102000010445 Lactoferrin Human genes 0.000 description 31
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 31
- 235000021242 lactoferrin Nutrition 0.000 description 31
- 229940078795 lactoferrin Drugs 0.000 description 31
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 20
- 235000006708 antioxidants Nutrition 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 229910052742 iron Inorganic materials 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 210000004379 membrane Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 17
- 239000000306 component Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 12
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 12
- 239000000843 powder Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229960005070 ascorbic acid Drugs 0.000 description 10
- 150000001768 cations Chemical class 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 235000010323 ascorbic acid Nutrition 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 229960000984 tocofersolan Drugs 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 229940087168 alpha tocopherol Drugs 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000002076 α-tocopherol Substances 0.000 description 8
- 235000004835 α-tocopherol Nutrition 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 4
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 229960003330 pentetic acid Drugs 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 2
- 108090000915 Aminopeptidases Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000607269 Vibrio proteolyticus Species 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 239000002781 deodorant agent Substances 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000011728 vitamin K2 Substances 0.000 description 2
- 235000019143 vitamin K2 Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 229910004354 OF 20 W Inorganic materials 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940009188 silver Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
Definitions
- the present invention relates to a composition containing apolactoferrin.
- Lactoferrin is a transferrin family iron-binding glycoprotein responsible for iron transport in the living body and was isolated in 1960. Regarding the function of lactoferrin, many studies have been conducted on bactericidal or bacteriostatic action, immune function regulating action, protection and growth of useful intestinal bacteria, suppression of free radicals (containing active oxygen), Research has progressed because bactericidal or bacteriostatic effects are clear. The mechanism of bactericidal or bacteriostatic is that lactoferrin attaches to bacterial and viral cell membranes and kills the bacteria directly by breaking the cell membrane, or lactoferrin takes away the iron necessary for the growth and maintenance of the bacteria, This is thought to be due to the effect of suppressing the survival of bacteria in a deficient state.
- Lactoferrin consists of about 690 chain amino acids, and its three-dimensional structure has two iron binding pockets, and iron binds to the pockets one by one.
- a material in which 100% of iron is bound to this pocket is called “hololactoferrin”, and a material in which iron is not bound is called “apolactoferrin”. Since normal bovine lactoferrin contains iron in 15 to 20% of the pockets, the powder and solution are pink, and the redness increases as the degree of binding of iron increases. On the other hand, apolactoferrin from which iron has been removed is white and can be easily distinguished by its appearance. Apolactoferrin has higher ironophilicity than normal lactoferrin and has a much higher antibacterial or bacteriostatic effect.
- Lactoferrin is also classified as an antioxidant because it binds and fixes free iron. This apolactoferrin having a large iron-fering action has a higher ability as an antioxidant than lactoferrin.
- apolactoferrin Since apolactoferrin has the useful properties as described above, it is used in various fields. For example, various compositions using apolactoferrin are known, such as ophthalmic compositions and cosmetics (Patent Documents 1 to 4).
- the Maillard reaction that occurs between various reducing sugars and proteins proceeds by the processing or storage of foods, imparts color or fragrance to processed foods, and further stabilizes food components, It is known to increase antioxidant activity or antimutagenicity.
- a terminal glycation product AGEs
- AGEs terminal glycation product
- Hemoglobin A 1C (HbA 1C ) is an Amadori transfer product in the early Maillard reaction and is not affected by diet, and thus is an important indicator for diagnosis of diabetes.
- the Amadori transition product reduces oxygen (O 2 ) by one electron to generate a superoxide anion which is active oxygen.
- the generated superoxide anion derives hydrogen peroxide (H 2 O 2 ) and a hydroxy radical (.OH).
- these active oxygens react with nitric oxide (NO) in the body to produce peroxynitrite (ONOO ⁇ ) having a high oxidizing power, and these free radicals are the organs of the delicate eye, kidney Injuries vascular endothelium.
- NO nitric oxide
- ONOO ⁇ peroxynitrite
- free radicals are the organs of the delicate eye, kidney Injuries vascular endothelium.
- generated (irreversible) AGEs are signaled into vascular endothelial cells, vascular smooth muscle cells, or macrophage cells via AGEs receptors (Receptor of AGEs; abbreviated as RAGE).
- RAGE AGEs receptors
- lactoferrin has high binding properties with AGEs, but the detailed research results have been announced since the 1990s. Lactoferrin has two domains that bind to AGEs, which have been found to be a loop of 17 to 18 amino acids. Since each end of this loop has a cysteine, it is sometimes called a cysteine loop. This loop has been shown to exhibit significant hydrophilicity, and binding sites such as lysozyme and defensin, which are peptides that are relatively easy to bind to other AGEs, also exhibit high hydrophilicity. It has been suggested that a hydrophilic environment is advantageous for binding to.
- the object of the present invention is to provide a useful composition containing apolactoferrin.
- the present invention provides a composition comprising apolactoferrin and at least one selected from the group consisting of a terminal glycation product binder, an antioxidant substance and an antibacterial substance.
- the glycation end product binder is a milk component hydrolyzate obtained by hydrolyzing whey with endoprotease, exoprotease, and endopeptidase.
- a composition exhibiting a useful effect is provided by combining apolactoferrin with a terminal glycation product binder, an antioxidant or an antibacterial substance.
- coli culture solution by apolactoferrin alone (no addition of glyceraldehyde-derived AGE), apolactoferrin when glyceraldehyde-derived AGE is added, and apolactoferrin and glycation end product binder when glyceraldehyde-derived AGE is added
- It is. 2 is a graph showing the antioxidant power of combinations of apolactoferrin and various concentrations of ⁇ -tocopherol. It is a graph which shows the antioxidant power of the combination of apolactoferrin and various concentrations of ascorbic acid.
- Apolactoferrin is a glycoprotein molecule from which iron bound in the lactoferrin molecule is released.
- the apolactoferrin used in the present invention is not particularly limited, but preferably has the following characteristics.
- Apolactoferrin preferably has an iron bond degree in the molecule of 5% or less, preferably 4% or less, more preferably 3% or less.
- the degree of iron binding refers to the ratio of the number of moles of iron to the number of moles of apolactoferrin.
- the degree of iron binding can be determined by measuring the absorbance of apolactoferrin by spectroscopic analysis, or by directly measuring the amount of iron in apolactoferrin by atomic absorption analysis or inductively coupled plasma (ICP) spectroscopy.
- the degree of iron binding refers to a value obtained by dissolving apolactoferrin powder in pure water to make a 1 w / v% solution, and measuring this at an absorbance of 470 nm.
- the total cation concentration in the aqueous solution is preferably 5 mmol / L or less.
- the total cation concentration is determined by dissolving apolactoferrin powder in 0.1N hydrochloric acid to prepare a 0.1 w / v% solution, and measuring the amount of each cation by atomic absorption photometry. And add them together.
- the total cation concentration may correspond to a salt (ion) contained as an impurity in the apolactoferrin powder.
- the total cation concentration is preferably 3 mmol / L or less, more preferably 1 mmol / L or less.
- Apolactoferrin can be usually produced by adjusting the pH of an aqueous solution containing lactoferrin to the acidic side to dissociate divalent iron ions of the lactoferrin molecule.
- Lactoferrin which is a raw material for apolactoferrin, is separated and purified from mammalian secretions such as milk (eg, milk) or processed milk products such as skim milk and whey (eg, whey) (eg, adsorbed on a cation exchange resin). Then, it may be obtained by utilizing a method of desorption with a high-concentration salt solution, a separation method by electrophoresis, a separation method by affinity chromatography, or the like. Further, it may be produced by various genetically modified cells (including microorganisms, plant cells, animal cells, insect cells, etc.), plants, animals and the like. Lactoferrin may be commercially available as pharmaceuticals, reagents, and the like.
- mammalian secretions such as milk (eg, milk) or processed milk products such as skim milk and whey (eg, whey) (eg, adsorbed on a cation exchange resin). Then, it may be obtained by
- Lactoferrin is preferably derived from natural products, more preferably from whey. Whey obtained as a by-product generated when producing a dairy product (for example, cheese, casein, etc.) from cow milk or skim milk can be suitably used as a source of lactoferrin.
- a dairy product for example, cheese, casein, etc.
- Apolactoferrin can be preferably produced, for example, by adding an acid to the solution when the lactoferrin-containing solution is ultrafiltered to dissociate iron ions bound to lactoferrin.
- the acid that can be used here include citric acid, hydrochloric acid, phosphoric acid, malic acid, and acetic acid (0.4 M or more), and citric acid is preferable.
- apolactoferrin is partitioned by these membranes in which bipolar membranes and cation exchange membranes, which are composite ion exchange membranes having a structure in which a cation exchange membrane and an anion exchange membrane are laminated, are alternately arranged. It can be suitably manufactured also by using an electrodialyzer having an acid chamber and a base chamber (for example, Patent Document 5). In this case, hydrochloric acid produced during the manufacturing process in the electrodialyzer is used as the acid.
- the pH on the acidic side to be adjusted is preferably 0.5 to 3, more preferably 1.5 to 2.5.
- the pH is close to neutral (for example, 5.5)
- the antibacterial properties of the obtained apolactoferrin may be weakened.
- a pH adjuster of an aqueous solution containing lactoferrin not only the acid but also phthalic acid, glycine and the like can be used. These pH adjusting agents are added to an aqueous solution containing lactoferrin in an amount suitable for adjusting the pH to the above value.
- the temperature at which the pH of the aqueous solution containing lactoferrin is adjusted to the acidic side is preferably not high considering protein denaturation. Usually, it is 5 ° C to 60 ° C, more preferably 15 ° C to 35 ° C, and even more preferably room temperature.
- apolactoferrin in the present invention will be described in detail in Preparation Example 1 below, but the production method of apolactoferrin is not limited to these. Moreover, you may modify
- apolactoferrin can usually be obtained in the form of an aqueous solution. You may use the form of aqueous solution, or you may use the form which removed the solvent and pulverized.
- a milk component hydrolyzate As the terminal glycation product binder, a milk component hydrolyzate can be suitably used. Milk component hydrolysates can be prepared by treating whey with endoproteases, exopeptidases, and endopeptidases. For this reason, it is also referred to as “whey hydrolyzate”. Whey is a milk-derived component in which casein, which is the main component of milk protein, is removed from raw milk (eg, milk). Whey obtained as a by-product generated when producing a dairy product (for example, cheese, casein, etc.) from cow's milk or skim milk can be suitably used for preparing a milk component hydrolyzate.
- casein which is the main component of milk protein
- the type of enzyme for treating whey and the mode of action are not limited.
- mammalian secretions such as milk (eg, milk) or skim milk can also be used, in which case the casein is removed prior to treatment with the enzyme. It is preferable to do.
- the processing conditions (including temperature and time) of the proteolytic enzyme for milk-derived protein in whey can be appropriately determined in consideration of protein denaturation and the enzyme's working temperature.
- the endoprotease is preferably bovine gastric mucosa-derived pepsin; EC3.4.23.1 is preferred, and the exopeptidase is preferably Aeromonas Proteolytica-derived aminopeptidase; EC3.4.11.10 is preferred, and the endopeptidase is bovine pancreas-derived chymotrypsin type II; EC3.4 .21.1 is preferred.
- the processing temperature of the endoprotease, exopeptidase, and endopeptidase enzyme is preferably 20-60 ° C, more preferably 40-60 ° C, and even more preferably about 50 ° C.
- the endoprotease, exopeptidase, and endopeptidase may act simultaneously or separately.
- the treatment time is preferably 0.5 to 5 hours, more preferably 1 to 3.5 hours.
- the ratio of the combination to act is Unit / 1 kg protein, preferably 1-1000: 1-10: 1-100, more preferably 100-1000: 1-2: 5-20 and even more Preferably, it is about 1000: 1: 10.
- a proteolytic enzyme In order to prepare a milk component hydrolyzate, it is preferable to cause a proteolytic enzyme to act on whey in substantially the same manner as in Preparation Example 2 below.
- the milk component hydrolyzate When the milk component hydrolyzate is contained in a product or composition, it may be in the form of an aqueous solution, or may be in the form of powder by removing the solvent (for example, by freeze drying).
- the milk component hydrolyzate has binding properties to AGEs, particularly glyceraldehyde-derived AGEs.
- AGEs particularly glyceraldehyde-derived AGEs.
- a milk component hydrolyzate when ingested as a food, a milk component hydrolyzate adsorbs food AGEs and inhibits absorption from the intestinal tract, thereby reducing the amount of AGE derived from glyceraldehyde that is converted from food AGEs in the body. .
- it when introduced into the body, it is useful as an anti-glyceraldehyde-derived AGE agent or as a preventive or therapeutic agent for diseases involving glyceraldehyde-derived AGE, for example, diabetes and its complications, or Alzheimer's disease.
- Monocytes which are known to increase blood AGEs concentration in patients suffering from diabetes or with aging, and increase blood AGEs (especially glucose-derived AGE), which is a marker of vascular disorders in blood Chemotactic activator (MCP-1) can also increase, but milk component hydrolysates can suppress the increase in MCP-1 that can be attributed to such increased levels of AGEs in the blood.
- MCP-1 Chemotactic activator
- the milk component hydrolyzate can preferably penetrate the skin.
- Such a milk component hydrolyzate can permeate a commercially available artificial skin membrane (for example, available from Toray Industries, Inc.).
- the artificial skin membrane may be a membrane capable of cutting off a molecular weight of about 2000.
- Such a milk component hydrolyzate can be used as a material for suppressing the accumulation of subcutaneous AGEs, and is used as a cosmetic.
- Antioxidant means any substance having free radical scavenging ability. Those having an excellent antioxidant effect or those having high safety to living bodies are preferable. Antioxidants that are suitable for the products in the fields detailed below or approved for application thereto are preferred. Examples of antioxidants include ascorbic acid, ⁇ -tocopherol, polyphenols (catechin, curcumin, anthocyanin, cacao mass polyphenol, isoflavone, rutin, etc.), carotenoids (lycopene, ⁇ -carotene, capsaicin, etc.), allyl sulfide, saponin, Examples include, but are not limited to sesamin. Antioxidants are readily available to those skilled in the art and can be obtained commercially or by means such as in-house preparation.
- the antibacterial substance refers to any substance having a bactericidal action, a sterilizing action, or a bacteriostatic action on bacterial cells. Those having excellent antibacterial action or those having high safety to living bodies are preferable. Antibacterial substances that are suitable for the products in the fields detailed below or approved for application thereto are preferred. As used herein, “antibacterial substance” excludes apolactoferrin.
- Antibacterial substances include, for example, citric acid, nisin, ascorbic acid, poly-L-lysine, glycine, methylparaben, cetylpyridinium chloride (CPC), benzoic acid, sorbic acid, silver, vitamin K2 (menaquinone), picolinic acid, imidazole 1,2-hexanediol, 1,2-pentanediol, 1,2-octanediol, 1,3-butylene glycol and the like, but are not limited thereto.
- the advanced glycation end product binders described above can also be used as antimicrobial substances.
- Antibacterial substances are readily available to those skilled in the art and can be obtained commercially or by means such as self-preparation.
- composition consisting of a combination can exert a useful action or effect in combination with at least one of a terminal glycation product binder, an antioxidant and an antibacterial substance.
- Apolactoferrin can enhance antibacterial properties in combination with a terminal glycation product binder, and can also exhibit antibacterial properties even in a state of excessive AGEs.
- Antioxidant power can be enhanced in combination with an antioxidant.
- Antibacterial properties can be enhanced in combination with antibacterial substances. Therefore, a composition comprising the combination shown above is provided.
- compositions comprising the combinations shown above can be used as a form of use by adding individual substances to the product separately (used as additives) so that the combination shown above is used, or from the combination shown above May be provided as a product comprising the composition.
- Such products may contain any other materials, additives, etc. as long as they do not interfere with the effect of the combination.
- Compositions comprising the combinations shown above include foods, cosmetics, mouth cleansing agents, topical skin preparations, ophthalmic products, surface coating agents (for example, food packaging containers or cans), polymer additives, deodorants (for example, , Deodorant mist), detergent, perfume and the like.
- an ophthalmic product can be prepared by combining apolactoferrin and an antimicrobial substance with ingredients that can be commonly used in ophthalmic products.
- the product may be in the form of a solution or may be in the form of powder by removing the solvent (for example, by lyophilization).
- the apolactoferrin is contained in the product in a concentration of, for example, 0.01 to 20, preferably 0.1 to 10, more preferably 0.5 to 5 (unit: w / v%).
- the terminal glycation product binder may be contained or added so as to have a concentration (unit: w / v%) of, for example, 0.05 to 20, preferably 0.1 to 10, more preferably 0.5 to 3.
- the antioxidant may be contained or added so as to have a concentration (unit: w / v%) of, for example, 0.01 to 10, preferably 0.05 to 5, more preferably 0.1 to 2.
- the antibacterial substance can be contained or added so as to have a concentration (unit: w / v%) of, for example, 0.01 to 10, preferably 0.05 to 5, more preferably 0.1 to 2.
- lactoferrin 10 kg of 50 mg / mL lactoferrin (manufactured by Fontera; iron binding degree is about 20%) was used.
- lactoferrin was treated with 0.1M citric acid.
- the lactoferrin solution was put into a supply tank of the apparatus, circulated for 10 minutes, and then circulated in the reverse direction for 5 seconds to concentrate the solution.
- the pressure and circulating fluid flow rate at the inlet and outlet of the UF membrane were set to 0.12 Mpa, 0.08 Mpa, and 15 L / min, respectively. This operation was repeated until the non-permeated concentrate was halved (this was defined as one round).
- the citric acid solution was put into the tank instead of the lactoferrin solution, and the same operation as above was performed for two rounds. Subsequently, 8 M ⁇ ⁇ cm or more of pure water was put into the tank, and the above operation was performed for 5 rounds to remove the acid remaining in the non-permeated concentrate.
- the temperature of the circulating liquid was in the range of 10 to 28 ° C. throughout the production process, and the pH was 2 to 3.
- the powder obtained by each acid treatment was apolactoferrin and the purity of apolactoferrin was measured using BIOXYTECH (registered trademark) Lacto f EIA TM (OXIS International Inc., Oregon, USA) after dissolving the powder in pure water. Determined by performing antibody quantification.
- the iron binding degree of the powder obtained by each acid treatment is dissolved in pure water so as to have a concentration of 1 w / v%, and then the amount of iron bound to apolactoferrin is measured at an absorbance of 470 nm. Determined by measuring.
- Table 1 shows the degree of iron binding of the obtained apolactoferrin.
- the iron bond degree was 2.95%.
- the total cation concentration of apolactoferrin having an iron binding degree of 2.95% was measured.
- 0.1N hydrochloric acid to the lyophilized powder of apolactoferrin, preparing a 0.1 w / v% apolactoferrin solution and measuring for Na, K, Ca, Mg, and Cu by atomic absorption spectrophotometry, these When the concentration of each cation was determined and the total was converted to the total cation concentration, the total cation concentration was 3.9 mmol / L.
- the lyophilized whey hydrolyzate was dissolved in pure water so as to be 10 mg / mL, and this was designated as A solution.
- a transverse membrane permeable cell having phases on both sides sandwiching an artificial skin membrane (Toray Industries, Inc.) was produced. Liquid A was put in one phase of the membrane permeation cell, and pure water was put in the other phase, and the whole cell was brought to a constant temperature by circulating water at 25 ° C. Both phases were stirred for 10 minutes at a speed of 120 rpm. After stirring for 10 minutes, the solution was taken out from the phase containing pure water, and this was designated as solution B.
- solution A solution before starting stirring
- solution B in which lyophilized whey hydrolyzate was dissolved in pure water were subjected to the conditions described below according to the method used in the transdermal absorption evaluation test.
- HPLC high performance liquid chromatography
- freeze-dried whey hydrolyzate (hereinafter simply referred to as “freeze-dried whey hydrolyzate”) that was freeze-dried after the enzyme treatment as described above was used.
- the obtained solution was made into a sterile solution by passing through a filter having a pore size of 0.22 ⁇ m in a clean bench.
- the lid of the 50 mL falcon tube was sealed with parafilm and incubated at 37 ° C. for 1 week to react DL-glucose and HSA.
- the solution was applied to a PD-10 column (GE Healthcare Bioscience) to remove unreacted DL-glucose, and the result was confirmed by HPLC to obtain a glucose-derived terminal glycation product (glucose-derived AGE) fraction. It was.
- DL-glyceraldehyde and 39 mg of diethylenetriamine-pentaacetic acid as a chelating agent were weighed and placed in a 50 mL falcon tube.
- 20 mL of 0.2 M phosphate buffer (pH 7.4) was added to the falcon tube, and DL-glyceraldehyde and diethylenetriamine-pentaacetic acid were dissolved with a vortex mixer.
- 500 mg of human serum albumin (HSA) (manufactured by Sigma) was added to the falcon tube and dissolved with a vortex mixer.
- the obtained solution was made into a sterile solution by passing through a filter having a pore size of 0.22 ⁇ m in a clean bench.
- the lid of the 50 mL falcon tube was sealed with parafilm and incubated at 37 ° C. for 1 week to react DL-glyceraldehyde with HSA.
- the solution was applied to a PD-10 column (manufactured by GE Healthcare Bioscience) to remove unreacted DL-glyceraldehyde, the result was confirmed by HPLC, and glyceraldehyde-derived glycation product (glyceraldehyde-derived AGE) ) A fraction was obtained.
- glucose-derived AGE or glyceraldehyde-derived AGE in the fraction obtained as described above was confirmed by an ELISA method using a monoclonal antibody.
- the anti-glucose-derived AGE monoclonal antibody or the anti-glyceraldehyde-derived AGE monoclonal antibody was consigned to Toyobo Co., Ltd. and produced from mice using glucose-derived AGE or glyceraldehyde-derived AGE as an antigen.
- anti-monoclonal antibodies are biotinylated with the biotinylation reagent EZ-Link (registered trademark) Sulfo-NHS-Biotinylation Kit (PIERCE, product code 21420), and the biotinylated anti-monoclonal antibody is labeled with streptavidin peroxidase (Nacalai Tesque, product). Code 02517-61) was coupled.
- any of the terminal glycation products prepared above and peroxidase-labeled streptavidin were bound to wells on which HSA antibodies (RayBiotech, Inc.) were immobilized. Biotinylated anti-monoclonal antibodies were added and chemiluminescence was detected to confirm the production of these terminal glycation products, glucose-derived AGE and glyceraldehyde-derived AGE.
- Example 1 Bacteria used for the antibacterial test were prepared as follows. Escherichia coli (NBRC 3972) purchased from the National Institute of Biotechnology, Biotechnology Headquarters (NBRC), was stored in a liquid by subculture in 5 mL of SCD bouillon (Nissui Pharmaceutical Co., Ltd.) . 50 ⁇ L of the stored E. coli solution was inoculated into 5 mL of SCD bouillon (Nissui Pharmaceutical Co., Ltd.) and cultured at 30 ° C. for 16 hours in a shaking water bath. The cultured bacterial solution was diluted with sterilized water to prepare 10-fold serial dilutions up to 10 7 -fold.
- a test series for examining antibacterial properties was prepared as follows. In a 96-well flat-bottom microplate (BDalFalcon), an 8 w / v% aqueous solution of apolactoferrin (prepared in Preparation Example 1) (sterilized with a filter having a pore size of 0.22 ⁇ m) was diluted several times with sterile water, and 50 ⁇ L each. A dilution series was prepared. The concentration of apolactoferrin in the wells was 0-2 w / v%.
- freeze-dried whey hydrolyzate (terminal glycation product binder) prepared in Preparation Example 2 is added to the addition series of glucose-derived AGE or glyceraldehyde-derived AGE so that the final concentration is 2.5 w / v%.
- a terminal glycation product binder addition series was also obtained.
- the microplate test system and the petri dish test system were cultured at 35 ° C. for 24 hours. After culturing, the test microplate was measured for turbidity (absorbance) at a wavelength of 630 nm with a microplate reader (Multiscan JX Thermo Labsystems), and the increase or decrease in the number of bacteria after the culture was examined.
- FIG. 2 shows the results of investigating the antibacterial properties of the combined use of apolactoferrin and a terminal glycation end product binder when a terminal glycation product is added (Figure 1: When glucose-derived AGE is added; Figure 2: Derived from glyceraldehyde) When AGE is added).
- FIG. 1 is a graph showing the absorbance in an E. coli culture solution by apolactoferrin alone (no addition of glucose-derived AGE), apolactoferrin when glucose-derived AGE is added, and apolactoferrin and a terminal glycation product binder when glucose-derived AGE is added.
- FIG. 2 shows an E.
- FIG. 1 is glucose-derived AGE
- FIG. 2 is glyceraldehyde-derived AGE
- the white squares represent the results when each AGE and the terminal glycation product binder were added to the apolactoferrin solution.
- Example 2 The bacterial cells were prepared in the same manner as in Example 1. Next, a 96-well flat-bottom microplate (BD Falcon) was diluted 8 times with an aqueous solution of 8 w / v% apolactoferrin (prepared in Preparation Example 1) using sterile water with a pore size of 0.22 ⁇ m. A 50 ⁇ L dilution series was prepared. The concentration of apolactoferrin in the wells was 0-2 w / v%.
- each apolactoferrin concentration system 50 ⁇ L each of various reagents (shown in Table 1 below) having been sterilized with a pore size of 0.22 ⁇ m and multiple dilutions of 8 w / v% with sterile water was added. was prepared.
- the combination reagents used are as follows: citric acid (Nacalai Tesque), lyophilized whey hydrolyzate (prepared in Preparation Example 2), nisin (SIGMA), ascorbic acid (Nacalai Tesque), poly -L-lysine (SERVA Electrophoresis GmbH), glycine (Wako Pure Chemical Industries, Ltd.), methylparaben (Wako Pure Chemical Industries, Ltd.), cetylpyridinium chloride (CPC) (Wako Pure Chemical Industries, Ltd.).
- Apolactoferrin and a combination reagent were combined at concentrations of 0, 0.03, 0.06, 0.13, 0.25, 0.5, 1 and 2 (unit: w / v%) to prepare a test system. Subsequently, these test systems were inoculated and cultured in the same manner as in Example 1, and the increase or decrease in the number of bacteria after the culture was examined.
- Antimicrobial properties were enhanced by combining any of the reagents used with apolactoferrin.
- Example 3 A dimethyl sulfoxide solution of 20 w / v% DL- ⁇ -tocopherol (CALBIOCHEM) was prepared. 5 ⁇ L of this was added to 500 ⁇ L of an aqueous solution of 2 w / v% apolactoferrin (prepared in Preparation Example 1), and then prepared with ultrapure water so that the ⁇ -tocopherol concentration was 0.1 w / v%. Similarly, ⁇ -tocopherol concentrations were adjusted to 0.05, 0.025, and 0.01 (unit: w / v%) to obtain test samples.
- test sample was subjected to FRAS4 (active oxygen / free radical automatic analyzer; Wismer Co., Ltd.) according to the manufacturer's protocol, and the antioxidant power was measured.
- FRAS4 active oxygen / free radical automatic analyzer
- FIG. 3 shows the antioxidant power of the combination of apolactoferrin and various concentrations of ⁇ -tocopherol.
- the horizontal axis represents the ⁇ -tocopherol concentration (%) (w / v) in the culture solution.
- the vertical axis shows the antioxidant power ( ⁇ mol / L).
- white circles show the results when ⁇ -tocopherol is used alone, and black circles show the results when ⁇ -tocopherol is added to the apolactoferrin solution. It became clear that it has an additive effect in the antioxidant effect.
- FIG. 4 shows the antioxidant power of combinations of apolactoferrin and various concentrations of ascorbic acid.
- the horizontal axis indicates the concentration (%) (w / v) of ascorbic acid in the culture solution.
- the vertical axis shows the antioxidant power ( ⁇ mol / L).
- the white circle represents the result when ascorbic acid alone, and the black circle represents the result when ascorbic acid was added to the apolactoferrin solution. It became clear that it has an additive effect in the antioxidant effect.
- foods, cosmetics, mouth cleansing agents, external preparations for skin, ophthalmic products, surface coating agents (for example, for food packaging containers or cans), polymer additives, deodorizing agents (for example, deodorizing mist) A composition that can be suitably used for detergents, perfumes and the like is obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Abstract
Description
アポラクトフェリンとは、ラクフェリン分子中に結合されている鉄が遊離した糖蛋白分子である。本発明で使用するアポラクトフェリンは特に限定されないが、以下の特性を有することが好ましい。
終末糖化産物結合剤としては、乳成分加水分解物が好適に用いられ得る。乳成分加水分解物は、ホエイをエンドプロテアーゼ、エキソペプチダーゼ、およびエンドペプチダーゼで処理することにより調製され得る。このため、「ホエイ加水分解物」ともいう。ホエイは、乳タンパク質の主成分であるカゼインが生乳(例えば牛乳)から取り除かれている乳由来成分である。牛乳または脱脂乳から乳製品(例えば、チーズ、カゼインなど)を製造する際に発生する副産物として得られるホエイは、乳成分加水分解物を調製するために好適に用いられ得る。
抗酸化物質とは、フリーラジカル捕捉能を有する任意の物質をいう。抗酸化作用が優れるもの、または生体への安全性の高いものが好ましい。以下に詳述する分野の製品に適した、あるいはそれらへの適用が認可されている抗酸化物質が好ましい。抗酸化物質としては、例えば、アスコルビン酸、α-トコフェロール、ポリフェノール類(カテキン、クルクミン、アントシアニン、カカオマスポリフェノール、イソフラボン、ルチンなど)、カロテノイド(リコピン、α-カロテン、カプサイシンなど)、硫化アリル、サポニン、セサミンなどが挙げられるが、これらに限定されない。また、抗酸化物質は当業者に容易に入手可能であり、市販または自家調製などの手段によって入手され得る。
抗菌物質とは、菌体への殺菌作用、滅菌作用、または静菌作用を有する任意の物質をいう。抗菌作用が優れるもの、または生体への安全性の高いものが好ましい。以下に詳述する分野の製品に適した、あるいはそれらへの適用が認可されている抗菌物質が好ましい。本明細書中でいう「抗菌物質」とは、アポラクトフェリンを除く。抗菌物質としては、例えば、クエン酸、ナイシン、アスコルビン酸、ポリ-L-リジン、グリシン、メチルパラベン、塩化セチルピリジニウム(CPC)、安息香酸、ソルビン酸、銀、ビタミンK2(メナキノン)、ピコリン酸、イミダゾール、1,2-ヘキサンジオール、1,2-ペンタンジオール、1,2-オクタンジオール、1,3-ブチレングリコールなどが挙げられるが、これらに限定されない。上で説明した終末糖化産物結合剤(特に、乳成分加水分解物)は、抗菌物質としても用いられ得る。また、抗菌物質は当業者に容易に入手可能であり、市販または自家調製などの手段によって入手され得る。
アポラクトフェリンは、終末糖化産物結合剤、抗酸化物質および抗菌物質のうちの少なくとも1種との組み合わせで有用な作用または効果を発揮し得る。アポラクトフェリンは、終末糖化産物結合剤との組み合わせで抗菌性を増強し得、またAGEs過多の状態であっても抗菌性を発揮し得る。抗酸化物質との組み合わせで抗酸化力を増強し得る。抗菌物質との組み合わせで抗菌性を増強し得る。したがって、上記に示した組み合わせからなる組成物が提供される。
マイクローザUFラボテスト機(LX-22001;旭化成ケミカルズ株式会社)に、同社製のUFモジュールであるLOV(中空糸モジュール:膜内径0.8mm、有効膜面積41m2、膜素材:ポリアクリロニトリル、公称分画分子量:50,000)を組み込んだ限外濾過装置を用いて、以下のようにアポラクトフェリンを製造した。
ウシの生乳からカゼインナトリウムを製造した後の残りのホエイをタツア・ジャパン株式会社から入手した。このホエイにエンドプロテアーゼ(ウシ胃粘膜由来ペプシン;E.C.3.4.23.1;シグマ社)1000Unit/1kgタンパク質、エキソペプチダーゼ(Aeromonas Proteolytica由来アミノペプチダーゼ;E.C.3.4.11.10;シグマ社)1Unit/1kgタンパク質、およびエンドペプチダーゼ(ウシ膵臓由来キモトリプシンII型;E.C.3.4.21.1;シグマ社)10Unit/1kgタンパク質を添加し、50℃にて3.5時間処理した。このような酵素処理により得られた加水分解物を凍結乾燥し、ホエイ加水分解物を得た。
カラム ODS(資生堂製) 4.6×150mm
溶離液 A:0.02%(v/v)TFA(溶媒H2O)
B:0.016%(v/v)TFA(溶媒ACN)
A:B=95:5(v/v)で使用
流速 0.75ml/分
温度 40℃
検出器UV 220nm。
まず、360mgのDL-グルコースおよびキレート剤として39mgのジエチレントリアミン-五酢酸をそれぞれ秤量し、50mLのファルコンチューブに入れた。次いでファルコンチューブに0.2Mリン酸緩衝液(pH7.4)を20mL添加して、ボルテックスミキサーにてDL-グルコースおよびジエチレントリアミン-五酢酸を溶解した。さらにファルコンチューブにヒト血清アルブミン(HSA)(Sigma社製)を500mg添加し、ボルテックスミキサーにて溶解した。次いで、得られた溶液をクリーンベンチ内でポアサイズ0.22μmのフィルターを通すことによって無菌溶液とした。パラフィルムにて50mLファルコンチューブの蓋を密封し、37℃で1週間インキュベートし、DL-グルコースとHSAとを反応させた。インキュベーション後、溶液をPD-10カラム(GEヘルスケアバイオサイエンス社製)にかけて未反応のDL-グルコースを除き、その結果をHPLCで確認し、グルコース由来終末糖化産物(グルコース由来AGE)画分を得た。
抗菌性試験に用いる菌体を以下のように調製した。独立行政法人 製品評価技術基盤機構 バイオテクノロジー本部 生物遺伝資源部門(NBRC)から購入した大腸菌(NBRC 3972)をSCDブイヨン(日水製薬株式会社)5mL中に継代培養法にて液体中に保存した。この保存していた大腸菌液50μLをSCDブイヨン(日水製薬株式会社)5mL中に接種し、振盪水浴中で30℃にて16時間培養した。培養後の菌液を滅菌水で希釈し、107倍までの10倍段階希釈液を調製した。
菌体の調製は、実施例1と同様に行った。次いで、96ウェル平底マイクロプレート(BD Falcon)に、8w/v%のアポラクトフェリン(調製例1にて調製)の水溶液(ポアサイズ0.22μmのフィルターで除菌)を滅菌水で倍数希釈し、各50μLの希釈系列を調製した。ウェル中のアポラクトフェリン濃度は、0~2w/v%であった。それぞれのアポラクトフェリン濃度の系に、ポアサイズ0.22μmのフィルターで除菌8w/v%の種々の試薬(以下の表1に示す)を滅菌水で倍数希釈したものを50μLずつ添加し、試験系を調製した。用いた組み合わせ試薬は以下の通りである:クエン酸(ナカライテスク株式会社)、凍結乾燥ホエイ加水分解物(調製例2にて調製)、ナイシン(SIGMA)、アスコルビン酸(ナカライテスク株式会社)、ポリ-L-リジン(SERVA Electrophoresis GmbH)、グリシン(和光純薬工業株式会社)、メチルパラベン(和光純薬工業株式会社)、塩化セチルピリジニウム(CPC)(和光純薬工業株式会社)。アポラクトフェリンおよび組み合わせ試薬をそれぞれ0、0.03、0.06、0.13、0.25、0.5、1、2(単位はw/v%)の濃度で組み合わせて試験系とした。次いで、これらの試験系に対して、実施例1と同様に菌体接種および培養し、培養後の菌の増減を調べた。最小発育阻止濃度(MIC)を決定し、fractional inhibitory concentration index (FIC index)を下記の計算式に従い算出した:
FIC index
=併用時のApo溶液MIC/単独時のApo溶液MIC+併用時の併用試薬MIC/単独時の併用試薬MIC
20w/v%のDL-α-トコフェロール(CALBIOCHEM)のジメチルスルホキシド溶液を調製した。この5μLを2w/v%のアポラクトフェリン(調製例1にて調製)の水溶液500μLに添加し、次いで超純水にてα-トコフェロール濃度が0.1w/v%となるよう調製した。同様にして、α-トコフェロール濃度が0.05、0.025、および0.01(単位はw/v%)となるよう調製し、試験試料を得た。
Claims (2)
- アポラクトフェリンと、終末糖化産物結合剤、抗酸化物質および抗菌物質からなる群から選択される少なくとも1種とからなる組成物。
- 前記終末糖化産物結合剤が、ホエイをエンドプロテアーゼ、エキソプロテアーゼ、およびエンドペプチダーゼで加水分解することにより得られる乳成分加水分解物である、請求項1に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010519792A JP5712429B2 (ja) | 2008-07-09 | 2009-07-08 | アポラクトフェリン含有組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-178652 | 2008-07-09 | ||
JP2008178652 | 2008-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010005012A1 true WO2010005012A1 (ja) | 2010-01-14 |
Family
ID=41507125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/062411 WO2010005012A1 (ja) | 2008-07-09 | 2009-07-08 | アポラクトフェリン含有組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5712429B2 (ja) |
WO (1) | WO2010005012A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2692355A1 (en) | 2012-08-01 | 2014-02-05 | Biagio Biancardi | Apolactoferrin for the treatment of iron accumulation diseases |
WO2015026747A1 (en) * | 2013-08-20 | 2015-02-26 | Trish Choudhary | Separating and demineralizing biomolecule solutions by electrodialysis |
IT202000009430A1 (it) | 2020-04-29 | 2021-10-29 | Tdc Tech Dedicated To Care Srl | Composizione per la prevenzione e/o il trattamento delle infezioni delle vie respiratorie |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62249931A (ja) * | 1986-04-21 | 1987-10-30 | Morinaga Milk Ind Co Ltd | 抗菌性組成物 |
JPH03181421A (ja) * | 1989-12-08 | 1991-08-07 | Chugai Pharmaceut Co Ltd | ベータラクタム系抗生物質の作用増強剤並びに感染症予防及び治療用の医薬組成物 |
JPH08112063A (ja) * | 1994-10-14 | 1996-05-07 | Morinaga Milk Ind Co Ltd | 風味良好な乳清蛋白加水分解物及びその製造法 |
JP2001054367A (ja) * | 1999-08-18 | 2001-02-27 | Morinaga Milk Ind Co Ltd | 乳化安定性の良好な栄養組成物 |
WO2007049757A1 (ja) * | 2005-10-27 | 2007-05-03 | Sunstar Inc. | ラクトフェリンを含んだリポソームを含有する破骨細胞増加抑制剤、経口組成物及び骨疾患の予防又は治療剤 |
JP2007137817A (ja) * | 2005-11-17 | 2007-06-07 | Hiroyoshi Inoue | 眼科用組成物およびコンタクトレンズ用組成物 |
JP2008063303A (ja) * | 2006-09-11 | 2008-03-21 | Up Well:Kk | 口内清浄剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2941093B2 (ja) * | 1990-06-26 | 1999-08-25 | 森永乳業株式会社 | ラクトフェリン分解物を有効成分とするチロシナーゼ活性阻害剤及びラクトフェリン分解物を用いる物品の処理方法 |
-
2009
- 2009-07-08 JP JP2010519792A patent/JP5712429B2/ja active Active
- 2009-07-08 WO PCT/JP2009/062411 patent/WO2010005012A1/ja active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62249931A (ja) * | 1986-04-21 | 1987-10-30 | Morinaga Milk Ind Co Ltd | 抗菌性組成物 |
JPH03181421A (ja) * | 1989-12-08 | 1991-08-07 | Chugai Pharmaceut Co Ltd | ベータラクタム系抗生物質の作用増強剤並びに感染症予防及び治療用の医薬組成物 |
JPH08112063A (ja) * | 1994-10-14 | 1996-05-07 | Morinaga Milk Ind Co Ltd | 風味良好な乳清蛋白加水分解物及びその製造法 |
JP2001054367A (ja) * | 1999-08-18 | 2001-02-27 | Morinaga Milk Ind Co Ltd | 乳化安定性の良好な栄養組成物 |
WO2007049757A1 (ja) * | 2005-10-27 | 2007-05-03 | Sunstar Inc. | ラクトフェリンを含んだリポソームを含有する破骨細胞増加抑制剤、経口組成物及び骨疾患の予防又は治療剤 |
JP2007137817A (ja) * | 2005-11-17 | 2007-06-07 | Hiroyoshi Inoue | 眼科用組成物およびコンタクトレンズ用組成物 |
JP2008063303A (ja) * | 2006-09-11 | 2008-03-21 | Up Well:Kk | 口内清浄剤 |
Non-Patent Citations (2)
Title |
---|
HIROYOSHI INOUE: "Aporakutoferin to Shumatsu Toka Sanbutsu (AGEs)", THE FOOD INDUSTRY, vol. 51, no. 12, 30 June 2008 (2008-06-30), pages 26 - 31 * |
SATOMI FURUNO ET AL.: "Seikatsu Shukanbyo Yobo ni Okeru Gaiinsei AGEs Kyuchaku Sozai no Tansaku", JMARS NEWS LETTER, vol. 5, 3 June 2008 (2008-06-03), pages 3, Retrieved from the Internet <URL:http://www.maillard.umin.jp/5th%20JMARS%20newsletter.pdf> [retrieved on 20090724] * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2692355A1 (en) | 2012-08-01 | 2014-02-05 | Biagio Biancardi | Apolactoferrin for the treatment of iron accumulation diseases |
WO2015026747A1 (en) * | 2013-08-20 | 2015-02-26 | Trish Choudhary | Separating and demineralizing biomolecule solutions by electrodialysis |
IT202000009430A1 (it) | 2020-04-29 | 2021-10-29 | Tdc Tech Dedicated To Care Srl | Composizione per la prevenzione e/o il trattamento delle infezioni delle vie respiratorie |
Also Published As
Publication number | Publication date |
---|---|
JPWO2010005012A1 (ja) | 2012-01-05 |
JP5712429B2 (ja) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2319475B1 (es) | Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion. | |
Jansson et al. | Green tea polyphenols decrease strecker aldehydes and bind to proteins in lactose-hydrolyzed UHT milk | |
de Freitas et al. | Structural features of procyanidin interactions with salivary proteins | |
Tavaf et al. | Evaluation of antibacterial, antibofilm and antioxidant activities of synthesized silver nanoparticles (AgNPs) and casein peptide fragments against Streptococcus mutans | |
JP5063947B2 (ja) | アクロレイン付加体形成阻害剤、及びそれを含有する皮膚抗老化外用剤および抗老化飲食品 | |
JP5712429B2 (ja) | アポラクトフェリン含有組成物 | |
JP2008056645A (ja) | 酵素処理されたローヤルゼリー中の蛋白質とポリペプチドとの反応により得られた抗酸化ペプチドおよびその製造方法 | |
WO2012043714A1 (ja) | 皮膚コラーゲン産生促進剤 | |
JP5017531B2 (ja) | 口内清浄剤 | |
JP5188523B2 (ja) | 骨形成促進及び骨吸収抑制剤 | |
WO2008032847A1 (fr) | Préparation externe pour la peau | |
JP2004231902A (ja) | 抗酸化性組成物 | |
JP2010229118A (ja) | リパーゼ阻害剤 | |
JP2006160630A (ja) | アクロレイン付加体形成阻害剤、及びそれを含有する皮膚外用剤及び健康補助食品 | |
JPWO2014020678A1 (ja) | 飲料及びその製造方法 | |
JP5537578B2 (ja) | ラクトフェリン加水分解物の製造方法 | |
RU2274003C2 (ru) | Способ комплексной переработки крови сельскохозяйственных животных для получения биологически активного вещества с противоанемическими свойствами на основе гемоглобина, биологически активное вещество с противоанемическими свойствами (варианты) и продукт, его содержащий (варианты). | |
Ouyang et al. | Structure relationship of non-covalent interactions between lotus seedpod oligomeric procyanidins and glycated casein hydrolysate during digestion | |
JP5714206B2 (ja) | 抗酸化剤 | |
JP4420576B2 (ja) | 安定な可溶性ビタミンa類組成物 | |
Diarrassouba | Interactions between ß-lactoglobulin and nutraceutical ligands riboflavin, vitamin D₃ and lysozyme: formation, physico-chemical and biological characterization of functional delivery scaffolds | |
Lei et al. | Partitioning and inhibition of hemoglobin-mediated lipid oxidation in chicken by components of black chokeberry press cake | |
Ranamukhaarachchi | Production and fractionation of antioxidant peptides from soy protein isolate using sequential membrane ultrafiltration and nanofiltration | |
JP4740532B2 (ja) | 骨形成促進及び骨吸収抑制剤 | |
Mukhopadhyay et al. | Elucidation of Lactoferrin and Lactoperoxidase in Separation Technique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09794456 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010519792 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17/02/2012) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09794456 Country of ref document: EP Kind code of ref document: A1 |